Acetylcholine release stimulated by nicotinic agonists was measured as radioactivity released from perfused synaptosomes prepared from mouse interpeduncular nucleus (IPN) that had been loaded with [
Nicotine exerts its primary effects via interaction with nicotinic receptors (nAChRs) which may exist as numerous subtypes with somewhat different pharmacology. The mRNA expression of some subunits (a4 and a7, b2) is widespread, whereas the expression patterns of others are restricted to a few regions Sargent 1993; Le Novere et al. 1996; Marks et al. 1996) . Nicotine modulates release of various neurotransmitters through the activation of presynaptic nAChRs (MacDermott et al. 1999) . The numerous different physiological and behavioral effects of nicotine could result from the release of different neurotransmitters via activation of various subtypes of nAChR at presynaptic terminals on several types of neurons. The ability to evaluate separately the numerous functions of presynaptic nAChRs would aid in determining exactly how nicotine changes brain function., A cholinergic projection from the medial habenula (MHb) through the fasciculus retro¯exus (fr) to the interpeduncular nucleus (IPN) exists. Lesioning studies have shown that this projection may be the sole source of cholinergic terminals in the IPN (Eckenrode et al. 1992) and that some or all of these neurons have presynaptic nicotinic receptors (Clarke et al. 1986) . In situ hybridization indicates that the MHb is an especially rich area for numerous nAChR subunits including a3, a4, a5, a6,a7, b2, b3 and b4 Sargent 1993; Le Novere et al. 1996; Marks et al. 1996) . High numbers of radioligand binding sites for epibatidine, nicotine, and a-bungarotoxin are located in the mouse IPN (Pauly et al. 1989; Marks et al. 1998; Whiteaker et al. 2000) . Thus, the potential for nAChR functional diversity in the IPN is extensive. Together, these data suggest the possibility that presynaptic nAChRs might modulate the release of acetylcholine in the IPN. Experiments reported here con®rm that presynaptic facilitation by nicotinic agonists of acetylcholine release from the IPN does indeed occur. This process has been characterized by an investigation of the agonist and antagonist pharmacology, the effects of a-conotoxins, the effect of the b2 null mutation, and a comparison to nAChR-mediated dopamine release. (3,4-[ring-2,5,6-3 H]-at 30±60 Ci/ mmol), or Amersham Pharmacia Biotech, Inc. (Piscataway, NJ, USA) (7, H-at 40±60 Ci/mmol). [ 3 H]Choline chloride (methyl-3 H-at 60±90 Ci/mmol) was a product of NEN Life Science Products. Sucrose, HEPES, ATP, and choline kinase were purchased from Boehringer-Mannheim (Indianapolis, IN, USA). Research Biochemicals International (Natick, MA, USA) was the source for (1)-anatoxin-a (ATXa), methylcarbamylcholine chloride (MeCARB), dihydro-b-erythroidine hydrobromide (DHbE), 3-(2-(S)-azetidinylmethoxy)pyridine (A-85380), and methyllycaconitine citrate (MLA). The following items were from Sigma Chemical, Co. (St. Louis, MO, USA): (±)-nicotine tartrate (L-NIC) (1)-nicotine-(1)-di-p-toluyltartrate (D-NIC), acetylcholine iodide (ACh), carbachol iodide (CARB) (1/±)epibatidine hydrochloride (EPI), cytisine (CYT) (1/±)-nornicotine (NORNIC) (1/±)-anabasine (ANAB), tetramethylammonium chloride (TMA), d-tubocurarine chloride (d-TC), hexamethonium chloride (HEX), decamethonium chloride (DEC), atropine sulfate, diisopropyluorophosphate (DFP), bovine serum albumin (BSA), sodium tetraphenyl boron (NaTPB), and EGTA. Dimethylphenylpiperazinium iodide (DMPP) and 3-heptanone were products of Aldrich Chemical Co. (Milwaukee, WI, USA). Mecamylamine (MEC) was a gift from Merck Sharp and Dohme Research Laboratory (Rahway, NJ, USA). The a-conotoxins MII and AuIB were synthesized as previously described (Cartier et al. 1996; Luo et al. 1998) .
Materials and methods

Materials
Animals
Mice, bred at the Institute for Behavioral Genetics (Boulder, CO, USA), were maintained on a 12-h light/12-h dark cycle (lights on from 7 AM to 7 PM), at 228C, with free access to food and water. Females of the C57BL/6 J strain, used as a source of tissue for most experiments, were housed ®ve to a cage. b2 nAChR subunit null mutant mice (Picciotto et al. 1995) were bred onto the C57BL/6 J strain for six generations and housed with same sex littermates, 2±5 to a cage. Genotype was determined by PCR analysis of tail DNA (Picciotto et al. 1995) . Animals were used at 60±90 days of age unless indicated otherwise. Animal care and experimental procedures were in accordance with the guidelines and approval of the Animal Care and Utilization Committee of the University of Colorado, Boulder.
Synaptosome preparation
Animals were killed by cervical dislocation and the brains were immediately placed on ice. The interpeduncular nucleus (IPN) was dissected with the aid of a magnifying glass. Because of the small size of the mouse IPN and the fragility of the synaptosomes prepared from this region, a modi®ed preparation was used. The IPN tissue from one or two mice was homogenized in a glassTe¯on homogenizer by 16 strokes by hand in 0.3 mL cold 0.32 m sucrose buffered to pH 7.5 with 5 mm HEPES. This homogenate, combined with two 0.3 mL rinses of the homogenizer tube, was centrifuged at 12 000 g for 20 min at 48C. The pellet (P1) was used without further puri®cation for the acetylcholine release experiments. Note that use of P1 and P2 pellets in the dopamine release assay indicated that results did not differ with the P1 preparation (data not shown). Crude synaptosomes were prepared from striatum as previously described (Grady et al. 1997) . The homogenized tissue was centrifuged at 3000 g for 10 min; then the supernatant (S1) was centrifuged at 20 000 g for 20 min. The pellet from the second centrifugation (P2) containing the synaptosomes was used for dopamine release experiments. H]choline (0.25 mm). After uptake, 10 or 20 mL aliquots of synaptosomes were placed directly onto 5 mm diameter ®lters (A/E glass ®ber from Gelman Sciences, Ann Arbor, MI) on the perfusion apparatus. For experiments with acetylcholine as agonist, 10 mm DFP was added for the ®nal 5 min of the uptake. This DFP treatment had no effect on acetylcholine release evoked by cytisine or potassium.
[ 3 H]Dopamine uptake Synaptosomes from striata of each mouse were resuspended in 0.8 mL perfusion buffer without BSA and with 1 mm ascorbate and 0.01 mm pargyline added. Addition of BSA at this step did not affect uptake, but was omitted to avoid foaming problems during the ®ltration of synaptosomes onto ®lters. The synaptosomes were incubated at 378C for 15 min with the addition of 4 mCi 
Perfusion and release
All experiments were conducted at room temperature using a perfusion apparatus described previously (Grady et al. 1992) . For acetylcholine release, buffer composition was identical to that used for uptake. For dopamine release, 0.1% BSA was added to the buffer used for uptake. Addition of BSA was found to increase the release response to nicotinic agonists without increasing baselines. This effect of BSA was limited to the transient phase of release and therefore shifts the EC 50 values determined in the presence of BSA and at short exposure times to those determined for transient release (see Grady et al. 1997) . Synaptosomes were perfused with buffer at 0.6 mL/min or 1.0 mL/min and fractions were collected at 30 s or 18 s intervals, respectively. The faster rate was used for experiments with shorter agonist exposures to ensure adequate exchange of solutions on the ®lters. Synaptosomes were exposed to agonists for de®ned periods of time during collection of fractions. Agonist or potassium exposure intervals were chosen independently for each type of experiment in order to provide adequate release while allowing for maximum ability to detect changes in release with genotype or prior treatments. Atropine (1 mm) was added to perfusion buffer when acetylcholine was used as agonist. There was no effect of atropine on release evoked by cytisine. For antagonist experiments, the concentration of agonist chosen was at or slightly above the EC 50 value for the agonist used (1 mm l-nicotine for dopamine release and 5 mm cytisine for acetylcholine release). Antagonists were added simultaneously with the agonists. Antagonists alone did not affect basal release. Econosafe (Research Products International, Corp., Mt. Prospect, IL, USA) (3 mL) was added to each fraction and radioactivity was determined by scintillation counting (1600TR Liquid Scintillation Spectrometer, Packard Instrument Co., Downer's Grove, IL, USA).
Data analysis
Instrument ef®ciency was 45% for counting tritium under the conditions used. The cpm were corrected by this factor for data expressed as dpm. For acetylcholine release, the instrument background level of 20 cpm was subtracted from all fractions as the baseline release was low enough that this background was a signi®cant fraction (10±20%) of the baseline release. Background subtraction was not necessary for dopamine release. After plotting cpm vs. fraction number, a baseline was calculated as a singleexponential decay from fractions collected prior to, and subsequent to, agonist stimulation using the non-linear curve-®tting algorithm of SigmaPlot 5.0 (Jandel Scienti®c, San Rafael, CA, USA). The calculated baseline was subtracted from each fraction and cpm minus baseline was then divided by the calculated baseline to give stimulated release as a fraction of unstimulated baseline cpm (units of release). Fractions with units of release greater than normal baseline variation (fractions over 0.1 units for dopamine release and over 0.3 units for acetylcholine release) were summed to determine total units of release.
For calculation of EC 50 or IC 50 values, the non-linear curve®tting algorithm of SigmaPlot 5.0 was used with weighted errors (weighting factor mean release/error Dopamine release can be divided into two phases termed transient and persistent (Grady et al. 1997) . Data for determining persistent and transient dopamine release from 10-min exposures to nicotine were calculated as previously described (Grady et al. 1997) . Brie¯y, units released per 30 s fraction were calculated as above and data points were ®t to a double-exponential equation,
using the non-linear least squares algorithm in SigmaPlot 5.0 (Jandel Scienti®c, San Rafael, CA). The parameters v T and v P are initial release for the transient and persistent phases, respectively, d T and d P are the desensitization constants for the two phases and t is the time of exposure to agonist.
Extraction of choline and acetylcholine
An extraction method that separates choline from acetylcholine was used (Fonnum 1969; Rowell and Winkler 1984) . Conditions for maximum extraction and conversion of choline to phosphocholine were determined using [ 3 H]choline. Using equal volumes (0.5 mL) of perfusion buffer and 50 mm NaTPB in 3-heptanone (20 mg/mL), choline was extracted by gentle mixing at room temperature for 10 min followed by centrifugation for 2 min at 330 g (Eppendorf Micro Centrifuge 5415C, Brinkmann Instruments, Inc., Westbury, NY). Re-extraction of the organic layer by perfusion buffer indicated the ef®ciency of extraction was 91%. For the enzyme-catalyzed conversion of choline to phosphocholine, 0.005±0.01 units of choline kinase, 1 mm ATP, 1 mm MgSO 4 and 3 mm EGTA were added to 0.5 mL perfusion buffer containing choline. This mixture was incubated at 378C for 10 min prior to extraction as described above. The perfusion assay was conducted with a preparation from two IPN divided onto eight ®lters. A 30-s exposure to either 50 mm potassium (on four ®lters) or 5 mm cytisine (on four ®lters) was used to stimulate release. Small aliquots from fractions collected were prepared for scintillation counting to determine which fractions contained high levels of released radioactivity. These peak fractions were combined, treated with choline kinase as above, and extracted. After scintillation counting of aqueous and organic layer aliquots, the amount of acetylcholine was determined as organic extractable counts corrected by the ef®ciency of extraction.
Results
Stimulation of acetylcholine release by cytisine, calcium dependence, and identi®cation of the released radioactive compound Release of radioactivity from IPN synaptosomes previously loaded with [ 3 H]choline was stimulated by nicotinic agonists and was concentration dependent. Data from representative individual ®lters illustrating the concentration dependence for cytisine-induced release is presented in Fig. 1(a) . For this release assay, cytisine appeared to be a full agonist. In contrast, cytisine is only a partial agonist in the dopamine and GABA release or Rb 1 ef¯ux assays previously investigated (Grady et al. 1997; Lu et al. 1998; Marks et al. 1999) . Cytisine was chosen as the agonist with which to characterize the assay, because of the combination of its high potency and ef®cacy.
To determine the dependence of the release on external calcium, synaptosomes from IPN, previously loaded with [ 3 H]choline, were perfused with either buffer containing 3.2 mm calcium or buffer with 4.8 mm NaCl substituted for the CaCl 2 . After a 12-min perfusion, release was stimulated by either potassium or cytisine. Figure 1( The identity of the radioactive compound released was determined by an extraction procedure described in the Materials and methods section. It was found that 74^3% (N 3) of the radioactivity released by 50 mm potassium was acetylcholine and 91^3% (N 4) of the radioactivity released by 5 mm cytisine was acetylcholine. These percentages are similar to those reported above for dependence on external calcium, possibly indicating that material released dependent upon external calcium is acetylcholine. Radioactivity released that was calcium-independent may be choline or some other non-quaternary metabolic product of choline. External calcium has also been shown to increase the activity of nAChRs, and this modulation may contribute to the high calcium dependence of agonist-evoked release (Booker et al. 1998) .
Agonist dose±response curves
Dose±response curves for the release of acetylcholine from IPN synaptosomes elicited by 13 agonists are shown in Fig. 2 . All points represent release stimulated by a 30-s exposure to agonist. Data were ®t to the Hill equation; the parameters are listed in Table 1 . Epibatidine was the most potent agonist tested and d-nicotine the least. l-Nicotine was ®vefold less potent than acetylcholine and fourfold more potent than d-nicotine, showing mild stereoselectivity. For most of the 13 agonists, Hill coef®cients were . 1. There was some day-to-day variation in maximal release (R max ); consequently, a 10-mm cytisine control was included with every experiment. When data were normalized to the cytisine control (last column of Table 1 ), none of the R max values were signi®cantly different from that determined for cytisine. This result indicates that all compounds tested were full agonists.
One possible explanation for ®nding that all of the agonists evoked nearly identical maximal release, is that this assay is limited by available acetylcholine. Such a limit could result in a failure to detect partial agonists as well as arti®cially increasing the Hill coef®cients. A shorter stimulation might evoke less release and determine whether or not the assay is limited by some mechanism such as availability of releasable acetylcholine, receptor desensitization, or desensitization of another component of the release process. A comparison of dose response curves for six ]choline, were washed on the perfusion apparatus for 12 min with either perfusion buffer or perfusion buffer in which the calcium chloride was replaced with equi-osmotic sodium chloride. After this 12 min wash, synaptosomes were exposed, for 30 s, to buffer containing cytisine or an elevated concentration of potassium, replacing an equi-osmotic concentration of sodium. Units are expressed as baseline-normalized response. Conditions for individual ®lters are as follows: ®lter 1, no calcium, 20 mM potassium, 4.7 units released; ®lter 2, with calcium, 20 mM potassium, 4.3 units released; ®lter 3, no calcium, 50 mM potassium, 11.3 units released; ®lter 4, with calcium, 50 mM potassium, 25.2 units released; ®lter 5, no calcium, 5 mM cytisine, 1.1 units released; ®lter 6, with calcium, 5 mM cytisine, 19.5 units released.
agonists using exposure times of 3 s and 30 s is presented in Fig. 3 , and the curve-®t parameters are listed in Table 2 . As expected for an assay where release is limited, the 3 s response was more than 10% of the 30 s release. Values determined ranged from 44% of the 30 s-value for acetylcholine to 77% for d-nicotine. The shift in EC 50 values of about threefold to higher concentrations, is another indication that the 30-s dose response curves are likely limited in maximum release by some mechanism. However, there was no signi®cant change in the Hill coef®cients, which suggested that the high Hill coef®cient of this release process is not an artifact of limited maximal acetylcholine release. These experiments also point out that while the EC 50 values may vary with changes in stimulation time, the rank order of EC 50 values is likely unchanged.
Inhibition by nicotinic antagonists
Inhibition of dopamine release from striatum (evoked by a 1-min exposure to 1 mm l-nicotine) and acetylcholine release from IPN (stimulated by a 30-s exposure to 5 mm cytisine) were compared using six antagonists. Both agonist concentrations are slightly above EC 50 values for the respective assays. Effects of the antagonists on acetylcholine release produced by a 30-s exposure to 50 mm potassium The parameters, EC 50 , and Hill coef®cient (n H ), are values determined by ®tting data points shown in Fig. 1 to the Hill equation (see Materials and methods). The value of R max as percentage 10 mM cytisine control is determined by calculating each data point as a percentage of the release stimulated by 10 mM cytisine for each synaptosome preparation. The value shown is the mean^SEM for the concentration of an agonist giving the highest release. None of these values are signi®cantly different from the value for cytisine by the t distribution. The parameters, EC 50 , and Hill coef®cient (n H ), are values determined by ®tting data points shown in Fig. 3 to the Hill equation (see Materials and methods). Ratios are a comparison of 3-s and 30-s data. R max in units normalized to a 30-s baseline (cpm released ± 18 s baseline)/ (30-s or 18-s baseline 4 0.6) was used to determine R max ratios.
were also determined. As seen in Fig. 4 , potassiumstimulated acetylcholine release was not inhibited by nicotinic antagonists, while all 6 antagonists inhibited agonist-evoked dopamine and acetylcholine release. IC 50 values are presented in Table 3 . While some antagonists have similar potency for blocking release in the two assays, others, notably DHbE, were quite different. Atropine (1 mm) had no effect on cytisine-evoked acetylcholine release (data not shown).
Inhibition by a-conotoxins
Previous experiments have established that a-conotoxin MII inhibits the rat a3b2 subtype of nAChR expressed in oocytes with an IC 50 value of 0.5 nm (Kulak et al. 1997 ). This toxin also partially inhibits dopamine release from rat striatum (Kulak et al. 1997) and mouse striatum, the latter with an IC 50 value of 2 nm (S.R. Grady, unpublished observation). a-Conotoxin AuIB blocks the a3b4 subtype of nAChR expressed in oocytes with an IC 50 value of 0.74 mm (Luo et al. 1998) . The results of experiments using these toxins to inhibit agonist-stimulated neurotransmitter release are presented in 3 H]dopamine, were exposed to the toxin for 5 min prior to agonist exposure. a-Conotoxin MII (50 or 100 nm) did not inhibit cytisine-stimulated acetylcholine release, but did inhibit the l-nicotine-evoked dopamine release by 35%. A similar procedure, using a 1-min exposure to a-conotoxin AuIB (10 mm), inhibited cytisine-stimulated acetylcholine release by approximately 50%, but did not inhibit nicotinestimulated striatal dopamine release. Effect of deletion of the b2 subunit of nAChR It has been previously shown that the release of dopamine and GABA stimulated by nicotine is absolutely dependent upon the b2 subunit (Whiteaker et al. 2000) . To determine the involvement of the b2 subunit of the nAChR in the acetylcholine release assay, experiments were carried out using IPN tissue from wild-type mice and mice heterozygous and homozygous for the b2 subunit null mutation. Data from male and female mice were combined as no signi®cant differences were seen between sexes. The effect of the b2 subunit null mutation on acetylcholine release evoked by potassium (18-s exposure), by three concentrations of cytisine (3-s exposure), and by three concentrations of l-nicotine (3-s exposure) is shown in Fig. 5(a) . A one-way anova detected no signi®cant effects of genotype for cytisine or nicotine-evoked release indicating that the nAChR subtype mediating acetylcholine release from mouse IPN does not require the b2 subunit. No signi®cant differences were found for potassium-stimulated release of acetylcholine, for baseline release prior to stimulation, or for uptake of [ 3 H]-choline. The previous observation, that 10 mm l-nicotine does not stimulate dopamine release from the b2 null mutant mice and evokes decreased release from mice heterozygous for the b2 null mutation (Whiteaker et al. 2000) , has been expanded here to examine several concentrations of lnicotine. The effect of the b2 null mutation on release of dopamine from striatal synaptosomes is shown in Fig. 5(b) . Signi®cant differences by one-way anova were found among the genotypes for the release of dopamine stimulated by a 30-s exposure to three concentrations of l-nicotine. Virtually no release was seen for the ±/±genotype with any of the l-nicotine concentrations used, con®rming that the b2 subunit is essential for nicotine-evoked dopamine release from striatal synaptosomes. A 25±30% reduction in release for the 1/2 genotype compared to the1/1genotype was measured. There was no effect of concentration of l-nicotine on the percent of decrease (for 1 mm l-nicotineevoked release from heterozygous mice was 70.4^3.1% of release from wild-type; for 3 mm l-nicotine, 72.5^0.8%; and for 10 mm l-nicotine, 74.9^4.0%), suggesting that the EC 50 value is not shifted in the heterozygous mice. No differences were seen for potassium-stimulated dopamine release, for baseline release prior to stimulation, or for uptake of [ 3 H]-dopamine into synaptosomes prepared from the different genotypes.
The effect of the b2 null mutation on dopamine release elicited by longer exposures to l-nicotine is presented in Fig. 5(c) . The homozygous null mutants have no transient or persistent release evoked by 10 mm l-nicotine. This result was con®rmed by assays using ®ve null mutant mice, male and female, 150±180 days of age (data not shown). The heterozygous and wild-type mice showed both transient and persistent phases of release. Curve ®ts of data from multiple experiments indicated that both phases are signi®cantly lowered in the heterozygous mice. A 40% decrease in transient release and a 49% decrease in persistent release were calculated, both of which were signi®cant by t-test (p , 0.001). No signi®cant changes were detected in desensitization rates.
Discussion
Assessment of nicotine-stimulated release of acetylcholine from synaptosomes prepared from the IPN of wild-type and b2 null mutant mice indicated that the b2 subunit is not necessary for forming the nAChR that mediates acetylcholine release in the IPN. In contrast, previously measured IC 50 values are from curve-®ts of data shown in Fig. 4 (see Materials and methods). For dopamine release, striatal synaptosomes were exposed to 1 mM L-nicotine for 1 min with or without antagonist present. For acetylcholine release, IPN synaptosomes were stimulated with 5 mM cytisine for 30 s with or without antagonist added. synaptosomal functions, including rubidium ef¯ux, dopamine and GABA release, mediated by nAChRs in mice have been shown to require the b2 subunit (Whiteaker et al. 2000) . Pharmacological differences, as well, indicate that the acetylcholine release assay measures function of a different nAChR subtype from the dopamine release, GABA release, or rubidium ef¯ux assays previously investigated in mice (Grady et al. 1997; Lu et al. 1998; Marks et al. 1999) .
Reports of agonist binding in b2 and a4 null mutant mice show that a substantial number of epibatidine binding sites, as well as some cytisine and l-nicotine binding sites, remain in the IPN in the absence of b2 or a4 subunits, con®rming the existence of a receptor population lacking b2 and/or a4 Marubio et al. 1999) . Agonist binding studies using selective inhibition have shown that several types of b2-independent binding sites are detectable (Whiteaker et al. 2000) . Several different functions of nAChRs have been measured in the habenulo-interpeduncular tract by electrophysiological techniques (Mulle et al. 1991) . Patch clamp recordings have shown that the b2 null mutation does not affect response to l-nicotine in the MHb (Picciotto et al. 1995) . These electrophysiological methods measure mostly postsynaptic responses from receptors located at somatodendritic sites while synaptosomal release measures receptors at presynaptic or preterminal sites. As reported here, agonist-induced release of acetylcholine from terminals in the IPN is not altered by the b2 null mutation, indicating that nAChRs on the cell soma of the MHb may be of a similar subunit composition to those on cholinergic terminals in the IPN. Fig. 5 Effect of the b2 null mutation on dopamine release from striatum and acetylcholine release from IPN. For (a), male and female mice, between the ages of 100±260 days, were assayed for acetylcholine release from IPN using a 12-s exposure to 50 mM potassium or a 3-s exposure to the indicated concentration of cytisine or L-nicotine. Units are baseline-normalized response. Data represent means^SEM for the following numbers of mice: for potassium, 81/1, 11 1/±, and 8 ±/±; for cytisine, 5 1/1, 7 1/±, and 4 ±/±; for L-nicotine, 3 1/1, 4 1/±, and 4 ±/±. Units are baseline-normalized response. No signi®cant differences were detected by one-way ANOVA. For (b), male and female mice, between the ages of 110±135 days, were assayed for [ The differential effect of the b2 null mutation on the dopamine and acetylcholine release assays unequivocally demonstrates that the two processes are mediated by different nAChRs. Experiments done in vivo demonstrate that wildtype mice respond to systemic l-nicotine with a signi®cant increase in extracellular dopamine level in the striatum, as measured by microdialysis, while the homozygous b2 null mutants do not . In the rat, systemic nicotine appears to elicit effects on dopamine release measured in the terminal ®eld by activation of nAChRs on cell bodies (Nisell et al. 1994) . Patch clamp recordings of the substantia nigra, the location of the cell bodies of dopaminergic terminals of the striatum, showed that somatodendritic nAChRs respond to l-nicotine in the wild-type, but not in the b2 null mutant mice . The results reported here con®rm that, in addition to somatodendritic receptors, the b2 null mutation affects nAChRs at dopaminergic terminals (see also Whiteaker et al. 2000) . Both phases of dopamine release, transient and persistent, require the b2 subunit. Consistent with reports of approximately 50% reduction of nicotine binding in the b2 heterozygotes (Picciotto et al. 1995; Lu et al. 1998; Whiteaker et al. 2000) , these heterozygotes have reduced levels of response to l-nicotine as measured by dopamine release from striatal synaptosomes. Desensitization parameters and the approximate EC 50 value for l-nicotine are not altered in heterozygotes, indicating that their receptors may not differ from those present in the wild-type mice.
a-Conotoxin AuIB inhibits nicotinic agonist-induced acetylcholine release from mouse IPN synaptosomes suggesting that this receptor may include a3 and b4 subunits. Luo et al. (1998) noted that a-conotoxin AuIB pretreatment produced inhibition (IC50 0.75 mm) of receptor function in oocytes that had been injected with a3 and b4 cRNA. The toxin was approximately 10-fold less potent in inhibiting the function of homomeric a7 nAChRs, while a 10-mm concentration of a-conotoxin AuIB was without effect on a4b4, a3b2, a4b2, a2b2, a2b4 and a1bgd receptors expressed in oocytes. It does not seem likely that an a7 nAChR mediates agonist-evoked acetylcholine release from the IPN because the IC 50 value for MLA of 3.9 mm far exceeds the K i value (1 nm) for MLA inhibition of [
125 I]-a-bungarotoxin binding to membranes prepared from mouse brain (M. Marks, unpublished observation) ) and more closely approximates the K i value of 2 mm for MLA inhibition of [ The experiments using a-conotoxin AuIB and those using the b2 null mutant mice, reported above, suggested that acetylcholine release from IPN may be at least partially mediated by receptors containing a3 and b4 subunits. Several studies have assessed the effects of a number of nicotinic agonists on rat a3b4 receptors expressed in Xenopus oocytes, and uniformly obtained a rank order of CYT . L-NIC $ ACh $ DMPP . CARB for agonist potency (Cachelin and Jaggi 1991; Luetje and Patrick 1991; Covernton et al. 1994) . For comparison, the rank order of agonist potency for acetylcholine release from mouse IPN synaptosomes was CYT . ACh $ DMPP . L-NIC . CARB (see Table 1 ). This comparison shows that the receptor that mediates acetylcholine release from mouse IPN synaptosomes is similar to the oocyte expressed a3b4 for agonists except for l-nicotine. However, it is known that pharmacological properties of nAChRs are affected by species and the cell type in which the nAChRs are expressed (Lewis et al. 1997) . For example, DMPP is more potent than cytisine for rat a3b4-nAChR expressed in HEK293 cells (Wong et al. 1995; Stetzer et al. 1996; Xiao et al. 1998) , whereas in oocytes cytisine is more potent than DMPP. Furthermore, oocytes injected with chick or human a3b4 mRNAs have yielded results that differ from those obtained using rat mRNAs (Wang et al. 1996; Chavez-Noriega et al. 1997; Gerzanich et al. 1997) . Receptor expression in oocytes and cell lines may not mirror the pharmacology of native receptors because of involvement of other subunits (a5, a6, b3, for example), post-translational modi®cations, differences in the membrane environment, and species or strain differences in levels of receptor and primary structure of the subunits (Wang et al. 1996; Lewis et al. 1997; GrootKormelink et al. 1998; Nelson and Lindstrom 1999; Vailati et al. 1999) . Con®rmation of the suggestion that the nAChR mediating acetylcholine release from mouse IPN synaptosomes contains a3 and b4 subunits, will require other techniques, perhaps assays with other null mutant genotypes.
Several reports have indicated that presynaptic autoreceptors regulate acetylcholine release from hippocampal and cortical synaptosomes or slices (Rowell and Winkler 1984; Araujo et al. 1988; Wilkie et al. 1996) . For assays of rat hippocampal synaptosomes, cytisine was reported to be a full agonist, though cytisine and l-nicotine were about equipotent, and DHbE was a more potent antagonist than mecamylamine (Wilkie et al. 1996) . This pharmacology differs considerably from the results obtained in mouse IPN synaptosomes where cytisine was also a full agonist but was substantially more potent than nicotine. Moreover, DHbE was considerably less potent than mecamylamine in inhibiting release. These results indicate that the nAChR presynaptic to cholinergic neurons in rat hippocampus is probably not of the same subtype as the nAChR presynaptic to mouse IPN cholinergic neurons.
The high EC 50 value for nicotine, measured for acetylcholine release from IPN, makes it unlikely that smoking levels of nicotine (Rose et al. 1999) would be able to activate this receptor. Desensitization of nAChRs usually occurs at lower agonist concentrations than activation; however, the recombinant human a3b4 subtype seems relatively resistant to desensitization by nM concentrations of nicotine (Olale et al. 1997) . For acetylcholine release, the observation that the EC 50 value can decrease with longer exposure to nicotine, makes it possible that chronic exposure to low concentrations might be suf®cient to stimulate the release of acetylcholine. Further experiments with this system will be required to assess this possibility.
